New Markers of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function in Sweat

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Status: Unknown

Conditions: Biomarkers; Cystic Fibrosis

Treatments: Diagnostic Test: Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)

Study type: Interventional

Funder types: Other

Identifiers

NCT03993600

2018/09OCT/374

Details and patient eligibility

About

The aim of the study is to identify new biomarkers of CFTR function in sweat and in sweat gland.

Full description

Sweat is a watery solution containing trace amounts of proteins and peptides that may contribute to the antimicrobial defense system of the skin barrier, playing a role in innate immune responses against potential pathogens. The peptide and metabolite composition of sweat has not been fully explored. Evidence suggests that the composition of the skin barrier could vary with diseases. The causes and consequences of the changes of sweat proteins and peptides in humans are unknown. This clinical trial will focus on multiomics analysis of sweat, mainly of the antimicrobial peptides that play a key role in the host-pathogen interaction. Antioxidants, anti-bacterial and anti-inflammatory compounds may contribute to the regulation of systemic inflammation and pathophysiological disorders. In cystic fibrosis, inflammatory responses are altered, exaggerated and persistent, even in the absence of infection. It is therefore relevant to study the influence of CFTR mutations on the profile of antimicrobial peptides expressed in sweat. The clinical study will potentially lead to the discovery of novel non-invasive biomarkers of the disease in sweat.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subject aged of 18 years or more.
• The patients with cystic fibrosis must have a confirmed diagnosis, be clinically stable, have a Forced Expiratory Volume in one second (FEV1) ≥ 30 and an O2 saturation ≥ 92%. F508del homozygous will been tested.
• Heterozygosity (parents of patients) will be confirmed by the presence of a single F508del mutation.

Exclusion criteria

• Presence of an acute infection
• Pregnancy and lactation
• Subjects currently included in another clinical trial
• Subjects with forearm skin alterations
• Subjects with signs of dehydration
• Smokers

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

30 participants in 3 patient groups

Healthy volunteers

Sham Comparator group

Description:

sweat test and skin biopsy

Treatment:

Diagnostic Test: Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)

Patients with Cystic fibrosis

Experimental group

Description:

sweat test and skin biopsy

Treatment:

Diagnostic Test: Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)

Heterozygotes subjects

Experimental group

Description:

sweat test and skin biopsy

Treatment:

Diagnostic Test: Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)